The U.S. biopharma sector demonstrated resilience in the first quarter of 2026, building on its recovery despite geopolitical and macroeconomic uncertainty. The market “hopped” forward on the back of robust M&A and supportive clinical catalysts. Biopharma outperformed broader indices with the XBI reaching a high of $132.09 and closing the quarter up 4.8%, versus a 4.6% decline in the S&P 500.
Public-market activity accelerated meaningfully, as the IPO window reopened with seven offerings raising $1.8 billion, marking the strongest quarter since Q4 2021. Secondary activity remained robust, with 64 transactions raising $10.5 billion, positioning 2026 to top 2025 issuance levels.
Strategic activity was equally constructive, with twelve M&A transactions exceeding $1 billion in value, of which four deals were greater than $5 billion, and an additional $6 billion in upfront partnering proceeds, as large pharma continues to address looming patent expirations and replenish pipelines.
As we move further into 2026, the William Blair biopharma team uncovers key financing and strategic trends along with our perspective on what hidden eggs may lie ahead in the coming months.
Complete the form below to download a copy of the report.